Precision Oncology in HER2 (ERBB2) Mutation and Guideline-Directed Targeted Therapies
October 23, 2026 – October 23, 2027
This activity is jointly provided by Global Education Group (Global) and GO2 for Lung Cancer.
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
The primary audience for this project is multidisciplinary healthcare professionals (HCPs) involved in the diagnosis, treatment, and longitudinal care of patients with advanced mNSCLC, including those with HER2 (ERBB2)-mutations. This includes medical oncologists, nurse practitioners, physician assistants, oncology pharmacists, molecular pathologists, oncology nurses and navigators, and other team members integral to diagnosis, biomarker testing, treatment selection, and toxicity management, especially those practicing in community, under-resourced, and rural settings, where disparities in access to biomarker testing and targeted therapies remain most pronounced.
Advances in precision oncology have transformed the treatment landscape for patients with HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC), creating new opportunities to improve outcomes through biomarker-driven care. As the understanding of HER2 biology continues to evolve, clinicians must remain current on the molecular characteristics, prognostic significance, and rapidly expanding therapeutic options available for this distinct patient population.
This educational activity provides an evidence-based overview of HER2 (ERBB2)-mutant NSCLC, reviewing the biology of HER2 alterations, their relationship to the broader ErbB signaling pathway, and the implications for tumor behavior and treatment resistance. Participants will examine current standards of care, including FDA-approved and guideline-directed therapies, compare outcomes with conventional and targeted treatment approaches, and review pivotal clinical trial data supporting emerging therapeutic strategies. The activity also explores mechanisms of action, treatment selection, and toxicity profiles to equip clinicians with practical knowledge for optimizing individualized care for patients with HER2 (ERBB2)-mutant NSCLC.
After completing this activity, the participant should be better able to:
1. Describe the clinical and molecular characteristics associated with HER2 (ERBB2) mutations.
2. Assess the prognostic implications of HER2 (ERBB2)-mutant NSCLC detection.
3. Describe outcomes of non-targeted (platinum-based chemotherapy, immunotherapy) and targeted therapies (directed antibody drug conjugate therapy, and HER2- selective tyrosine kinase inhibitor) regimens.
4. Discuss implications of the EGFR (epidermal growth factor receptor) and HER2 signaling pathways as both part of the ERBB2 family of receptor tyrosine kinases, and their central roles in non-small cell lung cancer (NSCLC) pathogenesis and the implications of their interactions for tumor biology, drug resistance, and treatment strategies.
5. Identify FDA-approved and national guideline-directed therapies, their mechanisms of action, and side effect profiles.
6. Describe clinical trial data supporting the use of targeted therapies for HER2 (ERBB2)-mutant NSCLC.
7. Summarize current national guideline-directed recommendations for first and second-line targeted therapy in HER2 (ERBB2)-mutant NSCLC.
Julia Rotow, MD
Assistant Professor of Medicine, Harvard Medical School
Clinical Director, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute
45-minute online activity
In support of improving patient care, this activity has been planned and implemented by Global Education Group and GO2 for Lung Cancer. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Global Education Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Education Group designates this continuing education activity for 0.75 contact hour(s) including 0.0 pharmacotherapeutic contact hour(s).
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are appropriately identified as relevant by Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners.
For information about the Joint Accreditation (ACCME, ANCC) of this activity, please contact Global at 303-395-1782 or [email protected].
